Study details
Enrolling now
Defibrotide for Sickle Cell Disease Patients Undergoing Stem Cell Transplant
New York Medical College
NCT IDNCT02675959ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
40
Study length
about 11 years
Ages
0.5–34
Locations
4 sites in CA, FL, NY +1
What this study is about
This trial is testing the safety and effectiveness of giving Defibrotide to adults and children with sickle cell disease who are undergoing a stem cell transplant. The goal is to see if this treatment helps prevent or treat sinusoidal obstructive syndrome (SOS), a serious complication after the transplant.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Defibrotide
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
defibrotide